一種新型渦輪導(dǎo)管被設(shè)計(jì)用于治療表淺股動(dòng)脈(SFA)的完全堵塞。該導(dǎo)管已經(jīng)獲得美國(guó)食品藥品管理局的許可。

這種2.5渦輪導(dǎo)管是CLiRpath系列的最新產(chǎn)品，是具有知識(shí)產(chǎn)權(quán)的受激準(zhǔn)分子激光導(dǎo)管，直徑從0.9mm～2.5mm不等。這種新激光具有幾種增強(qiáng)的設(shè)計(jì)功能。包括激光纖維數(shù)量增加，能夠多產(chǎn)生30%的能量，穿透速度快了60%，能夠消融較大的SFA和膝后動(dòng)脈；持續(xù)的發(fā)射激光隊(duì)列能夠使得手術(shù)時(shí)間縮短并減少放射暴露；水解被膜能夠產(chǎn)生更平滑地推進(jìn)至緊密的病變處，能夠較為容易地跨越動(dòng)脈分杈處。

許多患外周血管疾病和嚴(yán)重肢體缺血的患者出現(xiàn)完全堵塞，標(biāo)準(zhǔn)引導(dǎo)鋼絲不能穿過病變處，因此缺乏有效的治療選擇--或者進(jìn)行旁路手術(shù)或者截肢--這幾乎是不可避免的。CLiRpath為這些患者提供了截肢以外的治療選擇。

“我們最領(lǐng)先之處是穿越了關(guān)鍵的肢體缺血市場(chǎng)，通過增強(qiáng)我們現(xiàn)有產(chǎn)品，側(cè)重于SFA和膝蓋以下部位血管的完全堵塞這一難題，同時(shí)擴(kuò)大我們治療外周血管疾病領(lǐng)域，使用導(dǎo)管將會(huì)在下肢上部或者表淺股動(dòng)脈產(chǎn)生更大的內(nèi)腔。”Spectranetics(Colorado Springs, CO, USA)公司總裁兼首席執(zhí)行官John G. Schulte如此評(píng)價(jià)，正是該公司研制開發(fā)了這種新型渦輪導(dǎo)管。

Turbo Catheter Treats Total Occlusions
 
A new turbo catheter is designed to treat total occlusions in the superficial femoral artery (SFA). The catheter has been cleared by the U.S. Food and Drug Administration (FDA).

The 2.5 turbo catheter is the latest in the CLiRpath line of proprietary excimer laser catheters, ranging in diameter from 0.9 mm to 2.5 mm. This new laser features several design enhancements. These include an increased number of laser fibers, which create 30% more energy and 60% faster penetration rate to ablate larger lumens in the SFA and popliteal arteries; a continuous lasing train that will enable shorter procedure times and reduce radiation exposure; and a hydrophilic coating to allow for smoother advancement through tight lesions and an easier transition over the aortic bifurcation.

Many patients suffering from peripheral vascular disease and critical limb ischemia have total occlusions that cannot be crossed with standard guide wires, and have so few treatment options that surgery--either bypass or limb amputation--is nearly inevitable. CLiRpath provides an alternative to amputation for these patients.

“Our top priority is to further penetrate the critical limb ischemia market through enhancements to our current products focusing on long total occlusions in the SFA and below-the-knee applications, and also to expand our presence in the treatment of peripheral vascular disease with catheters that will generate larger lumens in the upper leg or the superficial femoral artery,” said John G. Schulte, president and CEO of Spectranetics (Colorado Springs, CO, USA), which developed the new turbo catheter.